HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rusch, V. W. Articles by Livingston, R. B. Search for Related Content PubMed PubMed Citation Articles by Rusch, V. W. Articles by Livingston, R. B.

The Annals of Thoracic Surgery, Vol 58, 290-294, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Neoadjuvant therapy: a novel and effective treatment for stage IIIb non- small cell lung cancer. Southwest Oncology Group

VW Rusch, KS Albain, JJ Crowley, TW Rice, V Lonchyna, R McKenna Jr, K Stelzer and RB Livingston
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

Neoadjuvant therapy has become an accepted treatment for stage IIIa, but not for stage IIIb, non-small cell lung cancer, which is usually considered incurable and treated nonsurgically. We determined the feasibility of neoadjuvant therapy in the setting of stage IIIb non- small cell lung cancer in a prospective multi-institutional trial. For patients to be eligible for entry into the study, they had to have pathologically documented T1-4 N2-3 disease. Treatment consisted of: (1) cisplatin (50 mg/m2) given on days 1, 8, 29, and 36 plus VP-16 (50 mg/m2) given on days 1 to 5 and 29 to 33, together with concurrent radiotherapy (4,500 cGy; 180 cGy per daily fraction); and (2) surgical resection performed 3 to 5 weeks after induction of medical therapy, if the response was stable, partial, or complete. Of the 126 total eligible patients entered into the study, 51 patients had stage IIIb tumors (24 with T4 tumors and 27 with N3 disease). This consisted of 34 men and 17 women with a median age of 57 years. Thirty-two (63%) patients (18 with T4 tumors and 14 with N3 disease) underwent resection of the primary tumor, with a 5.2% operative mortality. There was no difference in the operative time, blood loss, and length of hospital stay for the T4 versus the N3 patients. For all 51 patients, survival at 2 years was 39%. Sites of relapse in all patients were mainly distant, even though patients with N3 disease did not initially have involved N3 nodes resected.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. Doddoli, F. Barlesi, D. Trousse, S. Robitail, S. Yena, P. Astoul, R. Giudicelli, P. Fuentes, and P. Thomas One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 416 - 425. [Abstract] [Full Text] [PDF]

				C. A. DiPerna and D. E. Wood Surgical Management of T3 and T4 Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5038s - 5044s. [Abstract] [Full Text] [PDF]

				M. Semik, D. Riesenbeck, A. Linder, C. Schmid, P. Hoffknecht, A. Heinecke, H. H. Scheld, M. Thomas, and for The German Lung Cancer Cooperative Group Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1205 - 1210. [Abstract] [Full Text] [PDF]

				G. B. Ratto, R. Costa, G. Vassallo, A. Alloisio, P. Maineri, and P. Bruzzi Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer Ann. Thorac. Surg., July 1, 2004; 78(1): 234 - 237. [Abstract] [Full Text] [PDF]

				A. Cesario, S. Margaritora, D. Galetta, V. Porziella, P. Granone, R. M. D'Angelillo, L. Trodella, V. Cardaci, S. Sterzi, and P. Russo Correspondence re L. J. Wirth et al., Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, Then Surgery in Stage III Non-Small Cell Lung Cancer: a Phase I Study. Clin Cancer Res 2003;9:1698-704. Clin. Cancer Res., April 15, 2004; 10(8): 2902 - 2903. [Full Text] [PDF]

				D. Galetta, A. Cesario, S. Margaritora, V. Porziella, G. Macis, R. M. D'Angelillo, L. Trodella, S. Sterzi, and P. Granone Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach Ann. Thorac. Surg., December 1, 2003; 76(6): 1802 - 1809. [Abstract] [Full Text] [PDF]

				Y. Ichinose, Y. Fukuyama, H. Asoh, C. Ushijima, T. Okamoto, J. Ikeda, J. Okamoto, and M. Sakai Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer Ann. Thorac. Surg., December 1, 2003; 76(6): 1810 - 1814. [Abstract] [Full Text] [PDF]

				E. Cetinkaya, A. Turna, P. Yildiz, R. Dodurgali, M. A. Bedirhan, A. Gurses, and V. Yilmaz Comparison of clinical and surgical-pathologic staging of the patients with non-small cell lung carcinoma Eur. J. Cardiothorac. Surg., December 1, 2002; 22(6): 1000 - 1005. [Abstract] [Full Text] [PDF]

				J. Mouroux, N. Venissac, and M. Alifano Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer Ann. Thorac. Surg., November 1, 2001; 72(5): 1698 - 1704. [Abstract] [Full Text] [PDF]

				C. Doddoli, P. Thomas, X. Thirion, Y. Seree, R. Giudicelli, and P. Fuentes Postoperative complications in relation with induction therapy for lung cancer Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 385 - 390. [Abstract] [Full Text] [PDF]

				Y. Ohta, Y. Tanaka, T. Hara, M. Oda, S.-i. Watanabe, J. Shimizu, and Y. Watanabe Clinicopathological and biological assessment of lung cancers with pleural dissemination Ann. Thorac. Surg., April 1, 2000; 69(4): 1025 - 1029. [Abstract] [Full Text] [PDF]

				G. Stamatis, W. Eberhardt, G. Stuben, S. Bildat, O. Dahler, and L. Hillejan Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results Ann. Thorac. Surg., October 1, 1999; 68(4): 1144 - 1149. [Abstract] [Full Text] [PDF]

				E. A. Rendina, F. Venuta, T. D. Giacomo, A. M. Ciccone, G. Ruvolo, G. F. Coloni, C. Ricci, and S. G. A. Patterson INDUCTION CHEMOTHERAPY FOR T4 CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., February 1, 1999; 117(2): 225 - 233. [Abstract] [Full Text] [PDF]

				T. De Giacomo, E. A. Rendina, F. Venuta, G. D. Rocca, and C. Ricci Thoracoscopic Staging of IIIB Non-Small Cell Lung Cancer Before Neoadjuvant Therapy Ann. Thorac. Surg., November 1, 1997; 64(5): 1409 - 1411. [Abstract] [Full Text]

				D. Grunenwald, C. Mazel, P. Girard, G. Berthiot, C. Dromer, and P. Baldeyrou Total Vertebrectomy for En Bloc Resection of Lung Cancer Invading the Spine Ann. Thorac. Surg., February 1, 1996; 61(2): 723 - 725. [Abstract] [Full Text]

				D. J. Mathisen, J. C. Wain, C. Wright, N. Choi, R. Carey, A. Hilgenberg, M. Grossbard, T. Lynch, and H. Grillo ASSESSMENT OF PREOPERATIVE ACCELERATED RADIOTHERAPY AND CHEMOTHERAPY IN STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 123 - 133. [Abstract] [Full Text]

				T. W. Rice, D. J. Adelstein, A. Koka, M. Tefft, T. J. Kirby, M. A. Van Kirk, M. E. Taylor, T. E. Olencki, D. Peereboom, and G. T. Budd Accelerated Induction Therapy and Resection for Poor Prognosis Stage III Non-Small Cell Lung Cancer Ann. Thorac. Surg., September 1, 1995; 60(3): 586 - 591. [Abstract] [Full Text]

				D. J. Sugarbaker, J. Herndon, L. J. Kohman, M. J. Krasna, M. R. Green, t. C. a. L. G. B T. S. Group, and S. b. V. Rusch Results of cancer and leukemia group B protocol 8935A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung cancer J. Thorac. Cardiovasc. Surg., March 1, 1995; 109(3): 473 - 485. [Abstract] [Full Text]